Polypeptide Multilayer Nanofilms in Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Polypeptide Multilayer Nanofilms in Drug Delivery
Investigators are exploiting the tremendous structural diversity of polypeptides and their biophysical properties to develop novel drug carriers. Peptide-based materials hold out much promise for tailor-made targeting, penetration, and release of contents in a host of biological microenvironments.


Pharmaceutical Technology


Several charges are needed on a polymer for it to overcome the dissipative tendency of thermal energy and bind to a surface. This resembles the length requirement of an oligonucleotide to prime polymerization of the complementary DNA strand. Relatively little heat is exchanged on binding of a polyelectrolyte to an oppositely charged surface, so ΔG≈–TΔS, where G is free energy, T is temperature (in degrees Kelvin), and S is entropy. In other words, adsorption is largely driven by an increase in entropy. This increase is as a result of the release of small counterions to solution as side-chain charges in the newly adsorbed polymers form ion pairs with side chains of opposite polarity on the surface of the nanofilm. A useful compendium of essays on experimental and theoretical aspects of multilayer films is available (26), as is a brief summary of the physics of nanofilm fabrication (34).

It should be noted that the polyelectrolyte film fabrication method outlined above places no strict geometrical requirement for the substrate. Indeed, these films have been built on substrates of varying surface roughness and shape. Spherical particles in the nanometer to micrometer range have attracted considerable attention (27–28). There are three basic approaches with spherical particles: coating microparticles when the particles are the material of interest (29), trapping a material of interest that has been adsorbed onto template particles (30), and creating hollow spherical shells by dissolving the "dummy" template particles after nanofilm fabrication for subsequent "loading" and "release" of molecules of interest (31–33). All these approaches present interesting possibilities for systemic or local drug delivery.

Comprehensive studies

The work of the author's research group has been comprehensive, encompassing the physics, chemistry, and biology of multilayer nanofilms made of polypeptides (14, 21, 34). With regard to physics, we have investigated how the electric charge, hydrophobic surface, and side-chain hydrogen bonds of peptide structures contribute to PMN assembly, structure, and stability (35). Amino acid side chains have rather different chemical properties. With regard to biology, we have investigated how PMN designs influence cell behavior in vitro and in vivo (36–37). We have been especially interested in the extent to which we can control cellular phenotype in vitro or foreign body tissue reactions in vivo by encoding biological information in peptides for PMN fabrication.


Figure 2
In fundamental studies of the role of electronic charge density, hydrophobic interactions, and side-chain hydrogen bonds in PMN fabrication, structure, and stability (35), we have found that changes in peptide structure can have a surprisingly large impact on PMN fabrication, overall nanofilm thickness, and nanofilm density for a given number of polymer-adsorption steps during fabrication. Control over film thickness and density are potentially useful for determining the ability of the film to act as a diffusive barrier, which can provide differential controls over the rate of release of encapsulated materials (see Figure 2). We have validated PMN fabrication on a wide range of substrates with widely ranging electronic properties.

We have also explored coding regions of the human genome for sequences that are suitable for PMN fabrication (38). These sequences will generally have a large number of charged side chains per residue and a large net charge at neutral pH. Both conditions are needed for control over peptide solubility and binding affinity in PMN. Such sequence information is also potentially useful for controlling the immunogenicity of individual peptides and PMNs. PMNs intended for contact with blood, for instance, could be designed using sequence information from known blood proteins, tested experimentally, and modified as needed to achieve the desired properties.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
100%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
0%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Key Ways for Ensuring Global Regulatory Compliance
Source: Pharmaceutical Technology,
Click here